Episode 17. Acquired Aplastic Anemia
Blood Cancer Talks
The Role of JAC1-2 in the Treatment of Plastic Anemia
There are ongoing investigations in a fairly recent publication looking specifically at JAC1-2 inhibitors. I think as someone who treats MPNs with some regularity, my concern is Ruxilitinib is incredibly mild-suppressive in those patients. So I think we'll have to explore further what makes sense if this is a viable treatment.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
